Skip to main content

Table 2 Univariate association analysis for HCC recurrence

From: Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

  HCC, N = 17 No HCC, N = 103 p overall
Age 65 0.357
 <65 11 (64.7%) 80 (77.7%)
 > 65 6 (35.3%) 23 (22.3%)
Sex 0.735
 F 2 (11.8%) 20 (19.4%)
 M 15 (88.2%) 83 (80.6%)
AFP (ng/ml) 165 [6.70; 435] 7.10 [4.00; 39.1] 0.009
Waiting_time (days) 230 [31.0; 394] 211 [75.5; 344] 0.934
D (mm) 43.4 (20.0) 31.5 (20.6) 0.035
MELD 1.000
 MELD ≤ 15 12 (80.0%) 59 (72.0%)
 MELD = 15–30 2 (13.3%) 15 (18.3%)
 MELD > 30 1 (6.67%) 8 (9.76%)
preTreat 1.000
 No pre-treatment 6 (35.3%) 39 (37.9%)
 Pre-treatment 11 (64.7%) 64 (62.1%)
N 0.012
N = 1 1 (12.5%) 58 (63.0%)
N = 1–3 5 (62.5%) 25 (27.2%)
N > 3 2 (25.0%) 9 (9.78%)
Grade 0.045
 1 0 (0.00%) 23 (43.4%)
 2 5 (83.3%) 28 (52.8%)
 3 1 (16.7%) 2 (3.77%)
Asan < 0.001
 Exceeding 12 (70.6%) 23 (22.3%)
 Fulfilling 5 (29.4%) 80 (77.7%)
AFP score < 0.001
 > 2 12 (70.6%) 14 (15.9%)
 ≤ 2 5 (29.4%) 74 (84.1%)
MC 0.001
 Exceeding 13 (76.5%) 33 (32.0%)
 Fulfilling 4 (23.5%) 70 (68.0%)
UTS < 0.001
 Exceeding 13 (76.5%) 21 (20.4%)
 Fulfilling 4 (23.5%) 82 (79.6%)
  1. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for non-normally distributed data
  2. AFP alpha-feto protein in ng/ml, D diameter of the largest tumor in mm, MELD model of end-stage liver disease, N number of tumors, MC Milan criteria, UTS up-to-seven criteria